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Summary One hundred and fifty-nine previously untreated patients with small cell lung cancer (SCLC), who
were not eligible for intensive chemotherapy, were entered into a randomised study of intravenous (IV) doxorubicin and ifosfamide (with mesna) and oral etoposide. The IV drugs were given either by bolus therapy
or by a continuous infusion (CI) pump over 7 days via a central venous line. Therapy was given for 6 weeks only. On weeks 1, 3 and 5 IV doxorubicin 35 mg m-2 was given with 5 days of oral etoposide 100 mgm-2 daily. On weeks 2, 4 and 6 IV ifosfamide 5 g m-2 was given with equidose mesna. The overall median survival
was 25 weeks for patients in the bolus arm and 30 weeks for the CI therapy (P = 0.45). The overall response
rate was 64% (18% complete response - CR) and 69% (30% CR) respectively (P= 0.13). The median WHO score for haematological toxicity was 4 for bolus therapy and 3 for CI therapy (P = 0.0007). Despite a trend for less supportive care for patients on CI therapy there were no significant differences in the use of IV antibodies and blood or platelet transfusions. There were fewer treatment delays due to myelotoxicity in the CI arm (P = 0.04). The median WHO score for non-haematological toxicity was 2 in both treatment groups. There was significantly less nausea (P = 0.037) but more mucositis (P = 0.01) in the CI arm.
Weekly chemotherapy using CI treatment was as effective as bolus therapy. It was well accepted by patients. The assessment of quality of life in a subgroup of patients showed a statistically significant reduction in anxiety and depression for both groups of patients during therapy.
Small cell lung cancer is a chemosensitive tumour with a high
response rate to single agent chemotherapy - doxorubicin
35-45%, ifosfamide 50%, etoposide 40% (Monfardini et al.,
1987; Brade et al., 1985; Issell, 1982). Overall response rates
of about 60-90% have been reported with combination
chemotherapy (Morstyn et al., 1984).
However, despite the high response rate in many studies
patients with small cell lung cancer have a median survival of
only 12-16 months for limited stage disease and 8-12
months for extensive stage disease (Morstyn et al., 1984).
Prognostic factors have been identified so that intensive
chemotherapy can be targeted to patients in a better prog-
nosis group and those with a less favourable prognosis can
receive regimens that are less toxic and necessitate less hos-
pitalisation. Studies of shorter duration chemotherapy fol-
lowed by radiotherapy, or fewer courses of chemotherapy
followed by chemotherapy at relapse have not reduced sur-
vival (Bleehen, 1989; Spiro et al., 1989; Thatcher et al., 1982;
Thatcher et al., 1985).
Weekly chemotherapy schedules were introduced into the
treatment of non-Hodgkin's lymphoma (NHL) with an
associated high response rate (Blackledge et al., 1980; Klimo
& Connors, 1985). The Vancouver regimen allowed chemo-
therapy for NHL to be completed in 12 weeks instead of the
usual 6-12 months without compromising survival. We have
evaluated a weekly chemotherapy regimen in patients with an
intermediate or poor Manchester prognostic score (Table I,
Cerny et al., 1987), or for patients ineligible for intensive
chemotherapy because of age, prior malignancy or serious
concomitant illness that precluded entry into intensive
chemotherapy protocols despite a good prognostic score. The
aim was to minimise patient morbidity and the duration of
palliative chemotherapy.
Infusions of chemotherapy (e.g. doxorubicin) have been
shown to be associated with reduced toxicity compared with
bolus therapy (Vogelzang, 1984; Workman, 1992). This
randomised study of weekly doxorubicin and etoposide alter-
nating with ifosfamide has compared two routes of intra-
venous chemotherapy administration. In one arm the
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doxorubicin and ifosfamide were given by continuous
infusion by an ambulatory pump system and in the other
arm the agents were given by conventional bolus injection. Pharmacokinetic studies have shown that ifosfamide mixed
with mesna is stable for 7 days with no loss of alkylating activity (Bosanquet et al., 1985; Radford et al., 1990). Quality of life assessments are important in the evaluation
of chemotherapy given with palliative intent in order to
address the cost benefit equation. The two instruments for
measuring quality of life used in this study were recom-
mended by the working party advising the Cancer Therapy Committee of the Medical Research Council (Maguire et al., 1989). The Hospital Anxiety and Depression Scale (HADS) is a 14 item scale for use in medical out-patients to measure
anxiety and depression (Zigmond et al., 1983). The Rotter-
dam Symptom Checklist (RSCL) designed for use in cancer
patients, comprises 30 symptom items related to physical, psychological and functional status (deHaes et al., 1990). The aims of this study, which was submitted to and app- roved by the local ethics committee, were to assess response
rate, survival and toxicity - and in a subgroup of patients quality of life. In particular, we wanted to see if anxiety was
increased in patients using the pump method of treatment
delivery.
Materials and methods
Patients with previously untreated, histologically confirmed
small cell lung cancer were entered into the study after
Table I Manchester Score (Cerny et al., 1987)
Pre treatment variable Score
Serum sodium < 132 mmol -I + I
Serum alkaline phosphatase > 165 iu 1-' + I
Serum lactic dehydrogenase >450 iu 1' + I
Stage extensive + I
Karnofsky performance <60 + I
Serum bicarbonate <24 mmol I1' + I
Total
Good prognosis score 0,1: Intermediate prognosis 2,3: Poor
prognosis 4 +
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informed consent was obtained. Study patients had a Man-
chester score of 2 + (Cerny et al., 1987), or a score of 0 or 1
if the patient was aged >70 yrs, had received therapy for
prior malignancy or had cardiovascular disease that pre-
cluded the patient's entry into more intensive chemotherapy
studies (e.g. myocardial infarction within the last 30 days).
Patients were excluded from entry into the study if they
were outside the age range 18-75 yrs, had a creatinine
clearance of <50 ml min-', or had brain metastases.
Pre-treatment staging investigations included a full clinical
examination, assessment of Karnofsky performance (Karn-
ofsky et al., 1949), a full blood count, biochemical profile,
liver function tests, creatinine clearance, and a bone marrow
aspirate and trephine. Chest radiographs and upper abdom-
inal ultrasounds scans were routinely performed. Other
radiological investigations e.g. isotope bone scans were per-
formed as clinically indicated.
A subgroup of patients (those recruited in the latter half of
the trial) participated in quality of life assessments using
self-report questionnaires, HADS and RSCL. Both question-
naires were administered by a specialist nurse who explained
their purpose and ensured that they were completed and
scored. Each questionnaire reflected symptoms experienced
during the previous week. Three pairs of questionnaires were
completed-pretherapy, just before the 4th week of treatment
and at the first out-patient follow-up visit.
Treatment given
Therapy was given for 6 weeks only. On weeks 1, 3 and 5
doxorubicin 35 mg m-2 was administered intravenously con-
currently with 5 days of oral etoposide 100 mg m-2 daily. On
weeks 2, 4 and 6 ifosfamide 5 g m-2 was given with equidose
mesna intravenously. For those patients randomised to bolus
therapy ifosfamide admixed with mesna was given over 24 h
by infusion diluted in 21 normal saline. The doxorubicin was
administered as a bolus injection into a fast flowing normal
saline infusion. Patients randomised to continuous infusion
therapy had the ifosfamide or doxorubicin infused over 7
days. The ifosfamide for continuous infusion therapy was
dissolved in mesna and the volume made up with sterile
water to a maximum of 100 ml. The chemotherapy was then
infused via a nutricath central venous line, using a CADD
pump (Model 5100HF, Pharmacia Deltec Inc, St Paul, MN
55112 USA). The nutricath was inserted under local anaes-
thetic and the line tunnelled subcutaneously for about 10 cm.
Full blood counts were performed weekly on all patients,
and toxicity graded according to the WHO score (Miller et
al., 1981). Therapy was delayed by 1 week if the leucocyte
count was <3.0 x 109 1-l, the platelet count <100 x 109 1-',
or the creatinine clearance < 50 ml min-' on the day therapy
was due. No dosage reductions were made during the trial.
Results
From September 1987-June 1989, 159 previously untreated
patients with small cell lung cancer were entered into the
study; 82 patients were randomised to bolus therapy and 77
to infusion therapy. Patient characteristics are shown in
Table II. There was no significant difference in the age, sex
or stage of the patients in the two treatment groups. There
was an imbalance in the number of patients with a better
prognosis Manchester Score (0, 1)- 13% in the bolus arm
and 21% in the infusion arm (P = 0.3). The reason for the 27
'good prognosis' patients being entered into this study were:
coexistent cardiac disease (5), age> 70 yr (8), declined inten-
sive chemotherapy (3), protocol violation (3), prior malig-
nancy (1), severe atherosclerosis (4), and anxiety precluding
intensive chemotherapy (3).
There were seven protocol violations in the pump treated
group - refusal to accept therapy after randomisation (1),
incorrect randomisation (1), died before therapy given (1),
not small cell on histology review (4). There were four pro-
tocol violations in the bolus treatment group
- given a more
Table II Patient characteristics
Bolus (n = 82) Pump (n = 77)
(%) (%)
Male 49 (60) 34 (44) P= 0.07
Female 33 (40) 43 (56)
Median age (range) 61 (41-73) 62 (38-74)
Limited stage 39 (48) 42 (55) P = 0.47
Extensive stage 43 (52) 35 (45)
Manchester score
0,1 11 (13) 16(21) P=0.3
2,3 53 (65) 50 (65)
4+ 18(22) 11(14)
Karnofsky score
<50 24 (29) 24 (31)
60,70 38 (46) 36 (47) P= 0.78
80,90 20 (24) 17 (22)
Median no. weeks 6 (1-6) 6 (1-6)
therapy (range)
No. (%) completed 53 (65) 55 (71)
planned therapy
intensive chemotherapy (1), refused therapy after randomisa-
tion (1), not small cell histology (1), died before treatment
given (1).
Response to therapy
There were 14/78 (18%) complete responses in the bolus
treatment arm and 21/70 (30%) in the infusion chemotherapy
arm (P = 0.13). The overall response rates were 50/78 (64%
CI 52-75%) in the bolus arm and 48/70 (69% CI 56-79%)
in the infusion arm of the study (Table III). The median
duration of response was 20 weeks in the bolus arm and 26
weeks in the continuous infusion arm of the study. The
median time to maximal response was 53 days for bolus and
55 days for continuous infusion therapy compared with the
median of 63 days to complete bolus and 56 days to com-
plete continuous infusion therapy (delays being due to
myelotoxicity - see below).
Survival
The median survival (analysed by intention to treat) was 25
weeks for patients treated by bolus therapy and 30 weeks for
those treated with chemotherapy given by continuous
infusion (P = 0.45) (Figure 1). Analysis of survival allowing
for prognostic score and therapy showed no significant
difference between the two treatment groups (P = 0.88)
(Figure 2). The 1 year survival was 14% (95% CI 7-22%)
for bolus therapy and 19% (95% CI 11-30%) for con-
tinuous infusion therapy. The 2 year survival figures were 5%
for each arm (95% CI 1-13%). The overall median survival
was 36 weeks for limited stage and 22 weeks for extensive
stage disease (P<0.002). In patients with limited stage
disease the median survival was 33 weeks for bolus and 36
weeks for continuous infusion therapy (P = 0.88). For exten-
sive stage disease the median survival was 21 weeks for bolus
and 23.5 weeks for continuous infusion therapy (P = 0.43).
Table III Response to therapy
Bolus (n = 78) Pump (n = 70)
Complete remission 14 (18%) 21 (30%)
Partial remission 36 (46%) 27 (39%)
Stable 6 (8%) 9 (13%)
Progressed 8 (10%) 2 (3%)
Died before assessment 14 (18%) 11 (16%)
Median survival weeks 25 30 (P = 0.45)
(by intention to treat)
Median survial weeks 25 34 (P = 0.27)
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Figure 1 Survival according to treatment intent.
Toxicity
Eleven patients have been excluded from the toxicity analysis
as they were protocol violations and did not receive the
therapy to which they were randomised. There were 380
doses ofchemotherapy evaluable in the bolus arm and 359 in
the continuous infusion arm.
Haematological toxicity
The median WHO grade of the maximum haematological
toxicity for each patient was 4 in the bolus arm and 3 in the
infusion arm of the study (P = 0.0007). WHO grade 4 toxicity
was seen in 52/78 (67%) patients on bolus therapy and 24/70
(34%) patients on continuous infusion therapy. The median
WHO score for both leucopenia and neutropenia was 3 for
infusion and 4 for bolus therapy (P = 0.002/P = 0.033). The
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median WHO score for anaemia was 2 in each treatment
group (P= 0.58). The median WHO score for thrombo-
cytopenia was 0 for bolus therapy and 1 for infusion therapy
(P= 0.06). There was no significant difference in the use of
intravenous antibiotics, blood transfusions or platelet trans-
fusions between the two treatment groups (Table IV).
Non-haematological toxicity
The median WHO grade of non-haematological toxicity was
2 in each treatment group (P= 0.9). There was no docu-
mentation about the severity of nausea and vomiting in seven
bolus and 11 continuous infusion treated patients. No nausea
or vomiting, or nausea only occurred in 38/71 (54%) bolus
and 43/59 (73%) continuous infusion treated patients
(P = 0.037). There was no significant difference in renal tox-
icity between the two treatment groups 3/78 (4%) bolus
treated patients and 5/70 (7%) continuous infusion patients
had renal toxicity (P = 0.18). The toxicity was WHO grade 1
in all patients except one who had WHO grade 3 toxicity
(this patient had received bolus therapy).
Total alopecia was seen in 33/71 (46%) bolus therapy and
15/59 (27%) patients on continuous infusion therapy
(P<0.08).
Mucositis was seen in 24/78 (31%) patients on bolus
therapy and 37/70 (53%) patients on continuous infusion
therapy (P = 0.01).
Delays in therapy
No delays in therapy or a delay of only 1 week was seen in
24/78 (31%) bolus treated patients and 34/70 (49%) con-
tinuous infusion treated patients (P = 0.04). Only nine
patients completed the planned therapy within 6 weeks. Of
those patients who had treatment delays, there was a median
delay of 3 weeks for the bolus and 2 weeks for continuous
infusion therapy.
Quality oflife
Quality of life assessments were performed in a subgroup of
patients recruited in the latter half of the study, when desig-
nated personnel were available for this research. Sixty-three
patients agreed to participate, but of these ten died during
therapy, 12 stopped chemotherapy and four had missing
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Figure 2 Survival according to Prognostic Score and treatment intent.
Footnote: Median survival by Manchester Score.
Median survival (weeks)
Bolus Infusion
Good prognosis 49 43
Intermediate prognosis 24 27
Poor prognosis 22 9
Good vs intermediate vs poor P = 0.88*
Good vs rest P= 0.79*
*P values compare treatment allowing for prognostic group.1388 H. ANDERSON et al.
Table IV Supportive care
Patient number Courses oftherapy
Bolus Pump Bolus Pump
n = 78 (%) n = 70 (%) n = 380 (%) n = 359 (%)
IV antibiotics 49 (63) 40 (57) 69 (18) 55 (15)
P=0.67 P=0.35
Blood transfusions 45 (58) 29 (41) 62 (16) 40 (11)
P = 0.08 P = 0.053
Platelet transfusions 11 (14) 4 (6) 18 (5) 6 (2)
P=0.17 P=0.03
quality of life data. Thirty-seven (59%) patients had fully
evaluable data for the three assessment points. A further
three patients had assessable HADS data but missing RSCL
questionnaires.
The baseline scores for each treatment arm were compared
with respect to the HADS anxiety and depression subscales
and the RSCL psychological, physical and functional sub-
scales. No significant differences in the two arms existed
before therapy (unpaired t tests).
An important aspect of quality of life in this study was
psychological distress. The group median scores for both
treatment arms on the HAD scale pre-treatment were in the
upper end of the normal range (i.e. <8 - Table V). How-
ever, seven (18%) patients had scores in the range of prob-
able case depression (score > 11) and eight (20%) equivalent
levels of anxiety pretreatment. A further 11 (28%) patients
had scores in the range for borderline depression 3 (8%) and
anxiety 8 (20%).
The pretreatment group median scores on the RSCL
psychological subscale were 9.5 and 7.0 for the pump and
bolus arms respectively. Fourteen (38%) patients had scores
of > 11 indicating psychological distress. The RSCL does not
indicate a borderline level of distress.
Patients in both treatment arms showed a significant im-
provement in psychological symptoms on the RSCL during
the first half of therapy as shown in Figure 3 (Friedman's
one way ANOVA, P<0.002). Parallel improvement was
reflected by the Component SubscalesAof the HAD scale
(Table V).
Reduced psychological distress at the treatment mid-point
occurred despite an absence of improvement in physical
symptoms and a small increase in functional impairment at
this time, as measured by the relevant physical and functional
subscales on the RSCL.
No significant differences in any of the psychological
measures were found between patients receiving pump or
bolus therapy. Concerns that an infusion pump may have
caused anxiety were not confirmed.
Surprisingly no differences were seen in toxicity between
the two treatment groups using the self-reported physical
symptom items of the RSCL. Nor was there a significant
difference in functional status between the pump and bolus
therapy groups as measured by the RSCL eight activities of
daily living.
Figure 4 shows a comparison of scores for psychological,
physical and functional status. Scores for the treatment arms
have been combined as they were similar.
Table V Comparison of HADS Anxiety and Depression scores for
patients receiving chemotherapy by infusion pump (n = 22) or bolus
injection (n = 18)
HADS- Median score
Pre Mid Post
therapy therapy therapy P valued
HADS Anxiety Pump 7.0 4.5 4.0 P<0.03
Bolus 7.0 3.0 5.0 P = 0.002
HADS Depression Pump 6.0 5.0 3.0 P = 0.021
Bolus 5.5 3.0 2.5 P= 0.011
ap Friedman's one way ANOVA.
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Figure 3 Comparison of RSCL psychological complaints scores
at three time points for patients receiving chemotherapy by con-
tinuous infusion pump (n = 20) or bolus (n = 17).
Discussion
Six weeks' therapy was associated with a 63% response rate
overall and a median survival of 7 months. These results
compare favourably with an 18 week treatment regimen of
ifosfamide and etoposide in poor risk patients with small cell
lung cancer (Anderson et al., 1990), but less favourably with
a group of similar patients who received ifosfamide, doxo-
rubicin and etoposide every 3 weeks for six courses. These
patients had a median survival of 10.5 months (Kamthan et
al., 1990).
Weekly schedules have been used by other groups - the
Southwest Oncology Group reported an 82% response rate
in 76 patients with SCLC treated with combination chemo-
therapy using doxorubicin, cyclophosphamide, vincristine,
cisplatin and methotrexate, with weekly treatment for 16
weeks. The median survival was 16.6 months for limited
stage disease and 11.4 months for extensive stage disease
(Taylor et al., 1990).
Guys Hospital have also reported the results of weekly
chemotherapy for 70 'good prognosis' patients with SCLC
using cisplatin, etoposide, ifosfamide and doxorubicin for 12
weeks. Both limited stage and good prognosis extensive stage
patients were treated with a response rate of 91% and a
median survival of 58 weeks for limited stage and 42 weeks
for extensive stage disease (Miles et al., 1991).
In a study from Vancouver weekly CODE therapy (cis-
platin, vincristine, doxorubicin and etoposide) was given over
9-12 weeks to patients with extensive stage SCLC. A 94%WEEKLY THERAPY FOR SCLC - PUMP VS BOLUS - QUALITY OF LIFE 1389
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Figure 4 Comparison of physical, psychological and functional
status using RSCL for SCLC patients receiving chemotherapy.
response rate and a median survival of 61 weeks with a 2
year survival of 30% was obtained (Murray et al., 1991).
The patients in the study from Manchester had a poor
prognosis either because of a Manchester prognostic score of
two or more, age >70, prior malignancy or cardiovascular
disease that precluded the patient's entry into more intensive
chemotherapy studies. The overall response rate was 63%
and chemotherapy was only given for 6 weeks.
The response rate in our study was lower than that
reported in the other studies of weekly chemotherapy for
SCLC. This may be due to patient selection or duration of
therapy. We had 30% patients with a Karnofsky perfor-
mance score <50, whereas the other groups had 17%, none,
and 6% respectively (Taylor et al., 1990; Miles et al., 1991;
Murray et al., 1991). In addition the duration of treatment
was longer in these three studies - 16, 12 and 9-12 weeks
respectively. The time of maximal response in our study was
at the time of treatment completion.
The aim was to given chemotherapy weekly, however only
nine patients completed the therapy on time, delays being
due to myelotoxicity. The median delay was 3 weeks for
bolus and 2 weeks for continuous infusion therapy. The
future use of granulocyte colony stimulating factor or
granulocyte-macrophage colony stimulating factor may help
to alleviate myelotoxicity with this regimen.
The objective toxicity of the continuous infusion therapy
was significantly less than the bolus therapy with respect to
haematological toxicity, nausea and vomiting. Despite a
trend in favour of continuous infusion therapy there was no
statistically significant reduction in the need for antibiotic or
blood product support between the two treatment arms.
Renal toxicity was not a problem in the patients who
received ifosfamide by continuous infusion (without intra-
venous hydration).
The quality of life study showed that there was an im-
provement in psychological well-being before any subjective
improvement in physical or functional status. This was also
seen in a previous study of intensive chemotherapy for
patients with small cell lung cancer (Hopwood et al., 1990;
Hopwood et al., 1991). The patients on continuous infusion
pump therapy were treated as outpatients whereas those on
bolus therapy had at least an overnight admission for each of
their ifosfamide and mesna treatments. It was reassuring to
find that pump therapy was not associated with increased
anxiety, as expected, and this underlines the importance of
including self-report measures to detect the impact of treat-
ment. Other counter-intuitive results concerning quality of
life in palliative clinical trials of lung cancer (Earl et al.,
1991) and advanced breast cancer (Coates et al., 1987;
Richards et al., 1992; Tannock et al., 1988) are becoming
evident in the literature, endorsing the importance of this
research.
The lack of a significant difference in symptomatic toxicity
between the two treatment groups suggested similar toxicities
for the two approaches, whereas WHO scores favoured the
pump therapy for less nausea and vomiting and bolus for less
mucositis. However, the RSCL was administered only once
during active treatment and WHO scores were obtained
weekly. The quality of life assessments were started partway
through the trial and only substantial differences in toxicity
would have shown in this small sample.
Unfortunately only 59% patients recruited into the quality
of life study had evaluable data at all three assessment
points, highlighting a major problem in this type of research.
Attrition due to death or to patients becoming too ill to
participate will result in missing data. Collaborative research
would help to overcome the problems of small numbers, but
to ensure optimum collection of the available data we have
found it necessary to employ research nurses to administer
the quality of life questionnaires and assist with data man-
agement. The nurses have been trained in the techniques of
psychological assessment and can further evaluate patients
with emotional distress and where appropriate refer them for
further help. Both the HADS and the psychological com-
plaints subscale of the RSCL can be used to screen for
distress in this way. The need for additional resources to
ensure adequate data collection means that quality of life
research is costly in time and manpower, and partly explains
the lack of uptake of this approach in lung cancer trials to
date.
This study has shown that the weekly therapy is effective
in small cell lung cancer. Quality of life improved during
treatment and the use of an infusion pump was well tolerated
and probably reduced toxicity. The optimum duration of
therapy and dose intensity were not addressed in this trial
and need to be determined.
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